Literature DB >> 24525122

17β-Estradiol treatment inhibits breast cell proliferation, migration and invasion by decreasing MALAT-1 RNA level.

Ziyi Zhao1, Changjin Chen2, Yu Liu1, Chuanfang Wu3.   

Abstract

Breast cancer cells, which express estrogen receptor α (ERα), respond to estrogen in a concentration dependent fashion, resulting in proliferation or apoptosis. But breast cancer cells without ERα show no effect on low concentration of estrogen treatment. Proliferation, migration and invasion of MCF10a, MCF7 and MB231 cells treated with low (1 nM) or high (100 nM) dose of 17β-Estradiol (E2) was performed. We identified the effects of E2 on these breast cell lines, and looked for the difference in the presence and absence of ERα. Specifically, we looked for the changes of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 (MALAT-1), which is found extensively and highly expressed in several kinds of tumor cells, including breast carcinoma. It was observed that proliferation, migration and invasion of breast cells were greatly affected by high concentration E2 treatment and were not affected by low concentration E2 treatment in an ERα independent way. We found that the high concentration E2 treatment largely decreased MALAT-1 RNA level. Interestingly, MALAT-1 decreasing by knocking down showed similar effects on proliferation, migration and invasion. E2 treatment affects breast tumor or non-tumor cells proliferation, migration and invasion in an ERα -independent, but a dose-dependent way by decreasing the MALAT-1 RNA level.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  17β-Estradiol; Breast cells; Invasion; MALAT-1; Migration; Proliferation

Mesh:

Substances:

Year:  2014        PMID: 24525122     DOI: 10.1016/j.bbrc.2014.02.006

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  46 in total

Review 1.  Focusing on long noncoding RNA dysregulation in gastric cancer.

Authors:  Lu Gan; Midie Xu; Yi Zhang; Xia Zhang; Weijian Guo
Journal:  Tumour Biol       Date:  2014-12-13

2.  Mir363-3p improves ischemic stroke outcomes in female but not male rats.

Authors:  Amutha Selvamani; Farida Sohrabji
Journal:  Neurochem Int       Date:  2016-10-20       Impact factor: 3.921

3.  Long non-coding RNAs as novel biomarkers for breast cancer invasion and metastasis.

Authors:  Kaijiong Zhang; Zhenglian Luo; Yi Zhang; Xiaoyu Song; Li Zhang; Lichun Wu; Jinbo Liu
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

Review 4.  Long non-coding RNAs and nuclear factor-κB crosstalk in cancer and other human diseases.

Authors:  Subash C Gupta; Nikee Awasthee; Vipin Rai; Srinivas Chava; Venugopal Gunda; Kishore B Challagundla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-19       Impact factor: 10.680

Review 5.  The long noncoding RNA Malat1: Its physiological and pathophysiological functions.

Authors:  Xuejing Zhang; Milton H Hamblin; Ke-Jie Yin
Journal:  RNA Biol       Date:  2017-10-06       Impact factor: 4.652

6.  17β-estradiol regulates the malignancy of cancer stem-like cells derived from the MCF7 cell line partially through Sox2.

Authors:  Lian Guo; Feng Li; Mengyuan Wang; Yue Xu; Bangqiong Wang; Dongchuan Ran; Xianxiang Zhang
Journal:  Oncol Lett       Date:  2018-01-15       Impact factor: 2.967

Review 7.  Non-Coding RNAs in Endometrial Physiopathology.

Authors:  Alessandro La Ferlita; Rosalia Battaglia; Francesca Andronico; Salvatore Caruso; Antonio Cianci; Michele Purrello; Cinzia Di Pietro
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

Review 8.  Sex, epilepsy, and epigenetics.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Neurobiol Dis       Date:  2014-07-04       Impact factor: 5.996

Review 9.  Noncoding RNA control of cellular senescence.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2015-09-01       Impact factor: 9.957

10.  Novel insight into MALAT-1 in cancer: Therapeutic targets and clinical applications.

Authors:  Danyang Ren; Huiying Li; Renqiu Li; Jianming Sun; Pin Guo; Huiyun Han; Yuehuang Yang; Jun Li
Journal:  Oncol Lett       Date:  2016-01-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.